Page 95 - Read Online

Page 6 of 7 Onzi et al. Hepatoma Res 2019;5:7 I http://dx.doi.org/10.20517/2394-5079.2018.114

patients with non-alcoholic steatohepatitis. Hepatology 2010;51:1972-8.
10. Mahady SE, Adams LA. Burden of non-alcoholic fatty liver disease in Australia. J Gastroenterol Hepatol 2018;33:1-11.
11. Piñero F, Pages J, Marciano S, Fernández N, Silva J, et al. Fatty liver disease, an emerging etiology of hepatocellular carcinoma in
Argentina. World J Hepatol 2018;10:41-50.
12. Cotrim HP, Parise ER, Figueiredo-Mendes C, Galizzi-Filho J, Porta G, et al. Nonalcoholic fatty liver disease brazilian society of
hepatology consensus. Arq Gastroenterol 2016;53:118-22.
13. Said A, Ghufran A. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma. World J Clin Oncol 2017;8:429-36.
14. Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, et al. Risk of hepatocellular cancer in patients with non-alcoholic
fatty liver disease. Gastroenterology 2018;155:1828-37.
15. Ioannou GN, Green P, Lowy E, Mun EJ, Berry K. Differences in hepatocellular carcinoma risk, predictors and trends over time
according to etiology of cirrhosis. PLoS One 2018;13:0204412.
16. Reig M, Gambato M, Man NK, Roberts JP, Victor D, et al. Should patients with NAFLD/NASH be surveyed for HCC? Transplantation
2019;103:39-44.
17. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic
assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
18. Malik VS, Willett WC, Hu FB. Global obesity: trends, risk factors and policy implications. Nat Rev Endocrinol 2013;9:13-27.
19. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol 2017;67:862-73.
20. Wong SW, Ting YW, Chan WK. Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its
implications. JGH Open 2018;2:235-41.
21. Bulathsinhala BKS, Siriwardana RC, Gunetilleke MB, Niriella MA, Dassanayake A. Clinical characteristics and outcomes of
hepatocellular carcinoma: results from prospective study, from a tertiary referral center in Sri Lanka. Ceylon Med J 2018;63:133-8.
22. Mak LY, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, et al. Global epidemiology, prevention, and management of
hepatocellular carcinoma. Am Soc Clin Oncol Educ Book 2018;23:262-79.
23. Argyrou C, Moris D, Vernadakis S. Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic
steatohepatitis. Is it going to be the “Plague” of the 21st century? A literature review focusing on pathogenesis, prevention and
treatment. J BUON 2017;22:6-20.
24. Massoud O, Charlton M. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis and hepatocellular carcinoma. Clin Liver Dis
2018;22:201-11.
25. Rawla P, Sunkara T, Muralidharan P, Raj JP. Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol
(Pozn) 2018;22:141-50.
26. Nakagawa H, Hayata Y, Kawamura S, Yamada T, Fujiwara N, et al. Lipid metabolic reprogramming in hepatocellular carcinoma.
Cancers (Basel) 2018; doi: 10.3390/cancers10110447.
27. Reeves HL, Zaki MY, Day CP. Hepatocellular carcinoma in obesity, type 2 diabetes, and NAFLD. Dig Dis Sci 2016;61:1234-45.
28. Thompson SM, Garg I, Ehman EC, Sheedy SP, Bookwalter CA, et al. Non-alcoholic fatty liver disease-associated hepatocellular
carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI. Br J Radiol 2018;91:20180345.
29. Sadler EM, Mehta N, Bhat M, Ghanekar A, Greig PD, et al. Liver transplantation for NASH-related hepatocellular carcinoma versus
non-NASH etiologies of hepatocellular carcinoma. Transplantation 2018;102:640-7.
30. Wong CR, Njei B, Nguyen MH, Nguyen A, Lim JK. Survival after treatment with curative intent for hepatocellular carcinoma among
patients with vs without non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017;46:1061-9.
31. Tavakoli H, Robinson A, Liu B, Bhuket T, Younossi Z, et al. Cirrhosis patients with nonalcoholic steatohepatitis are significantly less
likely to receive surveillance for hepatocellular carcinoma. Dig Dis Sci 2017;62:2174-81
32. Balbinot RS, Muscope ALF, Dal Castel M, Balbinot SS, Balbinot RA, et al. Intraparenchymal hemorrhage due to brain metastasis of
hepatocellular carcinoma. Case Rep Gastroenterol 2017;11:516-25.
33. Soldera J, Balbinot SS, Balbinot RA, Furlan RG, Terres AZ. Advanced hepatocellular carcinoma. Austin J Gastroenterol 2017;4:1088.
34. Soldera J, Balbinot SS, Balbinot RA, Cavalcanti AG. Diagnostic and therapeutic approaches to hepatocellular carcinoma:
understanding the Barcelona Clinic Liver Cancer Protocol. Clin Med Insights Gastroenterol 2016;9:67-71.
35. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, et al. The diagnosis and management of nonalcoholic fatty liver disease:
practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328-57.
36. Pais R, Fartoux L, Goumard C, Scatton O, Wendum D, et al. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC
in patients undergoing liver resection over a 20-year period. Aliment Pharmacol Ther 2017;46:856-63.
37. Schütte K, Schulz C, Poranzke J, Antweiler K, Bornschein J, et al. Characterization and prognosis of patients with hepatocellular
carcinoma (HCC) in the non-cirrhotic liver. BMC Gastroenterol 2014;14:117.
38. Leung C, Yeoh SW, Patrick D, Ket S, Marion K, et al. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-
alcoholic fatty liver disease. World J Gastroenterol 2015;21:1189-96.
39. Bertot LC, Jeffrey GP, Wallace M, MacQuillan G, Garas G, et al. Nonalcoholic fatty liver disease-related cirrhosis is commonly
unrecognized and associated with hepatocellular carcinoma. Hepatol Commun 2017;1:53-60.
40. Edenvik P, Davidsdottir L, Oksanen A, Isaksson B, Hultcrantz R, et al. Application of hepatocellular carcinoma surveillance in a
European setting. What can we learn from clinical practice? Liver Int 2015;35:1862-71.
41. Mohamad B, Shah V, Onyshchenko M, Elshamy M, Aucejo F, et al. Characterization of hepatocellular carcinoma (HCC) in non-
alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatol Int 2016;10:632-9.
42. Zarrinpar A, Faltermeier CM, Agopian VG, Naini BV, Harlander-Locke MP, et al. Metabolic factors affecting hepatocellular
carcinoma in steatohepatitis. Liver Int 2018; doi:10.1111/liv.14002.
43. Kwon OS, Kim JH, Kim JH. The development of hepatocellular carcinoma in non-alcoholic fatty liver disease. Korean J Gastroenterol
2017;69:348-52. (in Korean)